# Cellogen Therapeutics

Source: https://onco.cc/companies/cellogen/  
OnCo record `cellogen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Delhi start-up developing bispecific CD19 and CD20 CAR-T cells and gene therapies for thalassaemia, aiming to cut treatment costs by up to 90%; still before its first trial.

## Summary

Cellogen Therapeutics is a New Delhi company developing bispecific, third- and fourth-generation CAR-T cells that target CD19 and CD20 at the same time to reduce antigen-loss relapse, plus genetic therapies for beta-thalassaemia and sickle cell disease. In its public statements it reports promising laboratory results and plans to begin clinical trials; it has no approved products. It is one of a growing group of Indian cell therapy start-ups following ImmunoACT and Immuneel, and its stated aim is to reduce treatment costs by up to 90% with indigenous products.

## Fields

- Kind: Company
- Status: preclinical
- Last checked: 2026-09-10
- HQ: New Delhi
- Type: cell-therapy
- Website: https://www.cellogentherapeutics.com

## Sources

- Official website: https://www.cellogentherapeutics.com

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/cellogen.json